Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG.

Curr Gene Ther. 2009 Oct;9(5):409-21. Review.


Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Curtin JF, King GD, Candolfi M, Greeno RB, Kroeger KM, Lowenstein PR, Castro MG.

Curr Top Med Chem. 2005;5(12):1151-70. Review.


Gene therapy for brain tumors: basic developments and clinical implementation.

Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG.

Neurosci Lett. 2012 Oct 11;527(2):71-7. doi: 10.1016/j.neulet.2012.08.003. Epub 2012 Aug 10. Review.


Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG.

Discov Med. 2010 Oct;10(53):293-304. Review.


An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.


Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.

Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, Castro MG.

Methods Mol Biol. 2016;1382:467-82. doi: 10.1007/978-1-4939-3271-9_31.


Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG.

Neuro Oncol. 2008 Feb;10(1):19-31. Epub 2007 Dec 13.


Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Redjal N, Zhu Y, Shah K.

Stem Cells. 2015 Jan;33(1):101-10. doi: 10.1002/stem.1834.


HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG.

PLoS Med. 2009 Jan 13;6(1):e10. doi: 10.1371/journal.pmed.1000010.


The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.


Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Oct 1;15(19):6113-27. doi: 10.1158/1078-0432.CCR-09-1087. Epub 2009 Sep 29.


Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG.

Clin Cancer Res. 2011 Jul 15;17(14):4705-18. doi: 10.1158/1078-0432.CCR-11-0915. Epub 2011 Jun 1.


Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG.

Mol Ther. 2008 Apr;16(4):682-90. doi: 10.1038/mt.2008.18. Epub 2008 Feb 19.


Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.


Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR.

Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review.


Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.

Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y, Nakano T.

Anticancer Res. 2015 Mar;35(3):1229-35. Review.


Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.

Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, Castro MG.

PLoS One. 2010 Jun 11;5(6):e11074. doi: 10.1371/journal.pone.0011074.


Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. doi: 10.1016/j.ijrobp.2012.12.025. Epub 2013 Feb 22.


Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

Clin Pharmacol Ther. 2010 Aug;88(2):204-13. doi: 10.1038/clpt.2009.260. Epub 2010 Feb 17.


Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR.

Mol Ther. 2011 Oct;19(10):1793-801. doi: 10.1038/mt.2011.77. Epub 2011 Apr 19.

Supplemental Content

Support Center